Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

72.20USD
1 Aug 2013
Price Change (% chg)

$-0.84 (-1.15%)
Prev Close
$73.04
Open
$73.50
Day's High
$73.61
Day's Low
$72.03
Volume
870,800
Avg. Vol
804,431
52-wk High
$74.59
52-wk Low
$57.40

BAX.N

Chart for BAX.N

About

Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.... (more)

Overall

Beta: 0.57
Market Cap (Mil.): $39,584.18
Shares Outstanding (Mil.): 541.95
Dividend: 0.49
Yield (%): 2.68

Financials

  BAX.N Industry Sector
P/E (TTM): 18.18 37.93 37.76
EPS (TTM): 4.02 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Baxter wins conditional EU clearance for Gambro takeover

BRUSSELS, July 22 - U.S. dialysis equipment maker Baxter International secured EU regulatory approval on Monday for its proposed $4 billion acquisition of Swedish peer Gambro AB after pledging to divest a unit to allay competition concerns.

22 Jul 2013

EU to clear Baxter's $4 billion buy of Sweden's Gambro: sources

BRUSSELS - EU antitrust regulators will approve a $4 billion bid by Baxter International Inc for Sweden's Gambro AB after the U.S. company offered to sell a unit to ease competition concerns, two people familiar with the matter said on Wednesday.

10 Jul 2013

UPDATE 2-EU to clear Baxter's $4 bln buy of Sweden's Gambro -sources

BRUSSELS, July 10 - EU antitrust regulators will approve a $4 billion bid by Baxter International Inc for Sweden's Gambro AB after the U.S. company offered to sell a unit to ease competition concerns, two people familiar with the matter said on Wednesday.

10 Jul 2013

CORRECTED-UPDATE 1-EU to clear Baxter's $4 bln buy of Sweden's Gambro -sources

(Corrects first sentence to clarify that CRRT unit represents 2 percent of Baxter's renal product sales, instead of nearly 20 percent of Baxter's total sales.)

10 Jul 2013

U.S. FDA approves new Baxter drug for hemophilia B

WASHINGTON - Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them.

27 Jun 2013

U.S. FDA approves new Baxter drug for hemophilia B

WASHINGTON, June 27 - Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them.

27 Jun 2013

Baxter's Alzheimer's disease drug fails in late-stage trial

NEW YORK - In a blow for Alzheimer's patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients.

07 May 2013

UPDATE 2-Baxter's Alzheimer's disease drug fails in late-stage trial

* Baxter to stop late-stage studies of the drug for mild to moderate Alzheimer's

07 May 2013

BRIEF-Baxter shares down after drug fails in late-stage trial

NEW YORK, May 7 - Baxter International Inc : * Shares down 2.6 percent in premarket trade after alzeheimer's drug fail

07 May 2013

Baxter's Alzheimer's disease drug fails in late-stage trial

May 7 - Baxter International Inc said a late-stage study of its experimental drug to treat Alzheimer's disease failed to reduce the decline of cognitive functions and preserve functional abilities.

07 May 2013

Competitors

  Price Change
Boston Scientific Corporation (BSX.N) $11.15 +0.23
Johnson & Johnson (JNJ.N) $93.77 +0.27
Abbott Laboratories (ABT.N) $36.84 +0.21
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
Pfizer Inc. (PFE.N) $29.11 -0.12
Wyeth Limited (WLED.NS) Rs666.25 -19.05
Hospira, Inc. (HSP.N) $42.03 +1.33

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Wright Reports
$495.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks